Impact of Viral Infections on Immune Microenvironment Alterations and Responses to Immune Checkpoint Therapy: Interactions Between Infection, Immunity, and Cancer - Scorecard - MDSpire

Impact of Viral Infections on Immune Microenvironment Alterations and Responses to Immune Checkpoint Therapy: Interactions Between Infection, Immunity, and Cancer

  • By

  • Guangying Wang

  • Feiyin Chen

  • Runda Zhao

  • Zhuoqi Liu

  • Xiaohong Yang

  • Daya Luo

  • April 27, 2026

  • 0 min

Share

Clinical Scorecard: Impact of Viral Infections on Immune Microenvironment Alterations and Responses to Immune Checkpoint Therapy: Interactions Between Infection, Immunity, and Cancer

At a Glance

CategoryDetail
ConditionCancer immunotherapy with immune checkpoint inhibitors (ICIs)
Key MechanismsViral infections influence tumor immune landscapes, driving T cell exhaustion and remodeling the tumor microenvironment.
Target PopulationPatients with solid tumors and concurrent viral infections (e.g., HBV, HCV, HIV, HPV, EBV).
Care SettingOncology clinics administering immunotherapy.

Key Highlights

  • ICIs can enhance antitumor immune function in patients with viral infections.
  • Viral infections may lead to improved responses to ICIs but also pose risks of viral reactivation.
  • Virus-specific immune profiling may guide individualized treatment strategies.

Guideline-Based Recommendations

Diagnosis

  • Assess viral infection status in cancer patients prior to ICI therapy.

Management

  • Consider combination therapies of ICIs and antiviral treatments.

Monitoring & Follow-up

  • Monitor for immune-related adverse events (irAEs) and potential viral reactivation.

Risks

  • Risk of viral reactivation during ICI therapy, particularly in immunosuppressed patients.

Patient & Prescribing Data

Patients with virus-associated malignancies receiving ICIs.

HPV-positive patients show higher response rates and overall survival with ICIs.

Clinical Best Practices

  • Integrate virological assessments into cancer treatment planning.
  • Utilize immune profiling to tailor immunotherapy approaches.

References

Original Source(s)

Related Content